Does rapamycin reverse or prevent gray hair?

Two studies using human cells and mouse models show that overactive mTORC1 in pigment cells (melanocytes) suppresses melanin production through a chain of molecular steps: increased oxidative stress in the endoplasmic reticulum and mitochondria, and reduced production of a protein (MITF) that drives the synthesis of the pigment enzyme tyrosinase. Rapamycin inhibited this mTORC1 signal and fully restored pigmentation in mice with genetically overactive mTORC1. The same mechanism was also observed in human melanocytes in culture and in skin biopsies from patients with tuberous sclerosis (a rare condition in which mTORC1 is permanently switched on due to an inherited mutation).

In a separate laboratory experiment using cultured human hair follicles, rapamycin stimulated both hair growth and pigmentation, even in already grey and white follicles that still contained a few living pigment cells. The effect worked through increased production of alpha-MSH, a hormone that activates pigment cells. This is currently the most direct lead for the question of whether rapamycin can address grey hair, but it involves tissue culture outside the body, not people taking the drug.

Not all laboratory results point in the same direction. In an experiment with melanoma cells stimulated with alpha-MSH, rapamycin had no inhibitory or stimulatory effect whatsoever on melanin production, although it did activate autophagy (a cellular cleaning process). This makes clear that rapamycin's effect on pigmentation depends strongly on cell type and specific conditions: there is no simple, universal mechanism of action.

As broader context, somatic mutations in the MTOR gene were found in skin cells of 14 out of 71 studied patients with segmental white skin patterns (a rare pigmentation disorder). This confirms that overactive mTORC1 can also disrupt pigment production in humans outside of hereditary diseases, but this concerns a rare condition that is not the same as ordinary age-related grey hair.

Clinical trials in humans examining rapamycin and grey hair do not exist. All available evidence comes from tissue culture and animal models, or from studies in patients with rare conditions in which mTORC1 is genetically dysregulated. Rapamycin is a potent immunosuppressant with serious side effects, and it is entirely unclear whether the effects seen in the lab would translate to ordinary ageing-related greyness in healthy people. At this time there is no basis for considering rapamycin as a treatment for grey hair.